MedPath

Vaxcyte Nears Critical Phase II Readout for 24-Valent Pneumococcal Vaccine

• Vaxcyte is preparing to release crucial Phase II safety and immunogenicity data for VAX-24, their 24-valent pneumococcal conjugate vaccine, by the end of the current quarter.

• The comprehensive infant trial will provide initial safety, tolerability, and immune response data, with follow-up booster dose results expected by year-end.

• This development comes amid broader regulatory uncertainties in the vaccine sector, with potential implications for the pneumococcal vaccine landscape.

Vaxcyte Inc. is approaching a significant milestone in its pneumococcal vaccine development program, with imminent Phase II clinical trial results that could reshape the pediatric vaccine landscape. The San Carlos, California-based biotechnology company is set to unveil top-line data for VAX-24, its innovative 24-valent pneumococcal conjugate vaccine (PCV), targeting one of the most common bacterial causes of serious infection in young children.

Clinical Trial Design and Expectations

The Phase II infant study focuses on three critical aspects: safety, tolerability, and immunogenicity of VAX-24. This comprehensive evaluation represents a crucial step in the vaccine's development pathway, with initial results expected before the end of the current quarter. The trial's design includes a subsequent booster dose assessment, with those results scheduled for release by the end of 2024.

Market Context and Strategic Timing

The timing of Vaxcyte's data release comes during a period of significant regulatory uncertainty in the vaccine sector and broader healthcare industry. This context adds particular weight to the upcoming results, as successful data could position VAX-24 as a potential advancement in pneumococcal disease prevention.

Potential Clinical Impact

VAX-24's development is particularly noteworthy due to its expanded coverage of pneumococcal serotypes. With 24 valents, the vaccine aims to provide broader protection against pneumococcal disease compared to currently available options. This expanded coverage could potentially address a significant unmet need in pediatric immunization programs.

Development Strategy

The phased approach to data release - with initial safety and immunogenicity results followed by booster dose data - demonstrates Vaxcyte's methodical strategy in vaccine development. This careful sequencing allows for thorough evaluation of the vaccine's performance at different stages of infant immunization.
The upcoming data readout will be closely watched by healthcare providers and industry observers, as it could signal a potential shift in the standard of care for pneumococcal disease prevention in infants. Success in this Phase II trial would represent a significant step forward in Vaxcyte's development program and could influence future directions in pediatric vaccine development.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Final Phase II Stage in Infant Trial

Vaxcyte has initiated the final stage of Phase II trials for VAX-31, its 31-valent pneumococcal conjugate vaccine, following successful safety review of Stage 1 data in infants.
VAX-31 demonstrates potential to provide approximately 94% coverage against invasive pneumococcal disease and 93% coverage for acute otitis media in U.S. children under five years.

Merck's CAPVAXIVE Receives Positive EU CHMP Opinion for Pneumococcal Vaccine

The European Medicines Agency's CHMP recommended CAPVAXIVE for active immunization against invasive pneumococcal disease and pneumonia in adults 18 and older.
CAPVAXIVE is designed to protect against Streptococcus pneumoniae serotypes responsible for the majority of invasive pneumococcal disease cases.

Pfizer Advances in C. diff Vaccine Development and Pneumococcal Shot Progress

Pfizer has made significant progress in its vaccine pipeline, particularly with its second-generation Clostridioides difficile (C. diff) vaccine now in Phase 2 and its fourth-generation 25-valent pneumococcal vaccine (PCV) also advancing. Analyst Chris Shibutani of Goldman Sachs maintains a Buy rating on Pfizer, highlighting the potential of these vaccines to address unmet medical needs.

Immix Biopharma's NXC-201 CAR-T Shows Promise in Relapsed/Refractory AL Amyloidosis

Immix Biopharma's NXC-201 demonstrates a 75% complete response rate in relapsed/refractory AL Amyloidosis patients, offering hope where no FDA-approved drugs exist.
The NEXICART-1 Phase 1/2 study highlights a 31.5-month best response duration, with the response ongoing, showcasing the potential long-term benefits of NXC-201.

enVVeno Medical Seeks FDA Approval for VenoValve in Severe Chronic Venous Insufficiency

enVVeno Medical has submitted its Premarket Approval (PMA) application to the FDA for VenoValve, a surgical replacement venous valve.
The VenoValve is intended for treating severe deep venous Chronic Venous Insufficiency (CVI), a condition affecting approximately 2.5 million people in the U.S. annually.

Valneva Seeks to Expand IXCHIQ Chikungunya Vaccine Label to Adolescents in Europe and Canada

Valneva has submitted label extension applications to the EMA and Health Canada for its chikungunya vaccine, IXCHIQ, to include adolescents aged 12-17.
The applications are supported by Phase 3 data demonstrating a 99.1% immune response in adolescents following a single dose of IXCHIQ.

GSK and CureVac Announce Positive Phase 2 Data for mRNA Seasonal Influenza Vaccine

GSK and CureVac's mRNA-based seasonal influenza vaccine program has demonstrated positive Phase 2 results, marking a significant step in novel vaccine development.
The vaccine showed an improved immune response compared to existing commercial vaccines, suggesting enhanced protection against influenza strains.

Vaxcyte's VAX-31 Shows Promise in Broad-Spectrum Pneumococcal Disease Prevention

Vaxcyte's VAX-31 vaccine demonstrated a favorable safety profile and strong immune response against all 31 serotypes in adults aged 50 and older.
The company's XpressCF platform enables the development of broad-spectrum vaccines that overcome the limitations of traditional cell-based approaches.

Vaxcyte's Pneumococcal Vaccine Candidate Outperforms Pfizer's Prevnar 20 in Early Trial

Vaxcyte's shares surged by 36% following the release of promising data on its pneumococcal vaccine candidate, VAX-24, which aims to rival Pfizer's Prevnar franchise.
In a preliminary trial involving 1,015 healthy adults aged 50 and older, Vaxcyte's VAX-24 demonstrated superior performance compared to Pfizer's Prevnar 20.

Vaxcyte's VAX-31 Demonstrates Positive Phase 1/2 Results, Advancing to Phase 3 for Pneumococcal Disease

Vaxcyte's VAX-31, a 31-valent pneumococcal conjugate vaccine, showed robust immune responses against all 31 serotypes in a Phase 1/2 study.
The vaccine was well-tolerated with a safety profile similar to Prevnar 20® (PCV20) in healthy adults aged 50 and older.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy